Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oral tenofovir arm of VOICE trial discontinued early.

× No keyword cloud information.

8 in total

1. Monoclonal and Single Domain Antibodies Targeting β-Integrin Subunits Block Sexual Transmission of HIV-1 in In Vitro and In Vivo Model Systems.

Authors: Janet Tai Guedon; Kun Luo; Hong Zhang; Richard B Markham
Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731

2. An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Authors: Shweta R Ugaonkar; Justin T Clark; Lexie B English; Todd J Johnson; Karen W Buckheit; Robert J Bahde; Daniel H Appella; Robert W Buckheit; Patrick F Kiser
Journal: J Pharm Sci Date: 2015-07-06 Impact factor: 3.534

3. 3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.

Authors: Minmin Li; Jiangman Duan; Jiayin Qiu; Fei Yu; Xiaoyan Che; Shibo Jiang; Lin Li
Journal: AIDS Res Hum Retroviruses Date: 2013-06-18 Impact factor: 2.205

Review 4. Translation of biomedical prevention strategies for HIV: prospects and pitfalls.

Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet
Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731

5. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

Authors: Milena Veselinovic; Kuo-Hsiung Yang; Jonathan LeCureux; Craig Sykes; Leila Remling-Mulder; Angela D M Kashuba; Ramesh Akkina
Journal: Virology Date: 2014-08-07 Impact factor: 3.616

6. Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures.

Authors: Isabella Bon; David Lembo; Marco Rusnati; Alberto Clò; Silvia Morini; Anna Miserocchi; Antonella Bugatti; Sonia Grigolon; Giuseppina Musumeci; Santo Landolfo; Maria Carla Re; Davide Gibellini
Journal: PLoS One Date: 2013-10-07 Impact factor: 3.240

7. Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues.

Authors: Sherrill L Macura; Melissa J Lathrop; Jiang Gui; Gustavo F Doncel; Susana N Asin; Christiane Rollenhagen
Journal: J Acquir Immune Defic Syndr Date: 2016-04-15 Impact factor: 3.731

8. Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.

Authors: Amanda Marie James; Jennifer R King; Ighovwerha Ofotokun; Anandi N Sheth; Edward P Acosta
Journal: J Exp Pharmacol Date: 2013-08-01

8 in total